Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
Laura Vangeel, Winston Chiu, Steven De Jonghe, et al.
Antiviral Research (2022) Vol. 198, pp. 105252-105252
Open Access | Times Cited: 391
Structural biology of SARS-CoV-2: open the door for novel therapies
Weizhu Yan, Yanhui Zheng, Xiao‐Tao Zeng, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 250
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 118
Two Years into the COVID-19 Pandemic: Lessons Learned
Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 9, pp. 1758-1814
Open Access | Times Cited: 112
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 104
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 82
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
Michihito Sasaki, Koshiro Tabata, Mai Kishimoto, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 679
Open Access | Times Cited: 80
Therapeutics for COVID-19
Sima S. Toussi, Jennifer Hammond, Brian S. Gerstenberger, et al.
Nature Microbiology (2023) Vol. 8, Iss. 5, pp. 771-786
Open Access | Times Cited: 73
SARS‐CoV‐2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control
José L. Gonzáles, Denise A. Marston
EFSA Journal (2023) Vol. 21, Iss. 2
Open Access | Times Cited: 48
Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus
Robert W. Cross, Courtney Woolsey, Victor C. Chu, et al.
Science (2024) Vol. 383, Iss. 6688
Open Access | Times Cited: 18
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Alexandra Schäfer, David R. Martinez, John J. Won, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 643
Open Access | Times Cited: 70
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
Jared Pitts, Jiani Li, Jason K. Perry, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 6
Open Access | Times Cited: 64
Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study
Aldo Marrone, Riccardo Nevola, Ausilia Sellitto, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 1, pp. e403-e409
Open Access | Times Cited: 61
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White, Joshua T. Schiffer, Rachel Bender Ignacio, et al.
mBio (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 58
Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
Daniele Focosi, Fabrizio Maggi, Scott A. McConnell, et al.
Antiviral Research (2022) Vol. 198, pp. 105247-105247
Open Access | Times Cited: 56
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Zhonglei Wang, Liyan Yang, Xian-qing Song
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 48
Aptamers for SARS‐CoV‐2: Isolation, Characterization, and Diagnostic and Therapeutic Developments
Ryan Amini, Zijie Zhang, Jiuxing Li, et al.
Analysis & Sensing (2022) Vol. 2, Iss. 5
Open Access | Times Cited: 46
Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19
Arun K. Ghosh, Jennifer L. Mishevich, Andrew D. Mesecar, et al.
ChemMedChem (2022) Vol. 17, Iss. 22
Open Access | Times Cited: 46
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model
Carolin M. Lieber, Robert M. Cox, Julien Sourimant, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
Sheli R. Radoshitzky, Patrick L. Iversen, Xianghan Lu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
Richard L. Mackman, Rao Kalla, Darius Babusis, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 11701-11717
Open Access | Times Cited: 31
Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2
Mohamed S. Bekheit, Siva S. Panda, Adel S. Girgis
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115292-115292
Open Access | Times Cited: 26
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 10
Coronaviral RNA-methyltransferases: function, structure and inhibition
Radim Nencka, Jan Šilhán, Martin Klíma, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. 2, pp. 635-650
Open Access | Times Cited: 55
Page 1 - Next Page

Scroll to top